ADMA Biologics Inc (NASDAQ:ADMA) insider Adam S. Grossman acquired 485,000 shares of the business’s stock in a transaction on Thursday, November 9th. The shares were purchased at an average price of $2.15 per share, for a total transaction of $1,042,750.00. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website.

ADMA Biologics Inc (NASDAQ:ADMA) opened at $2.75 on Wednesday. The company has a quick ratio of 1.35, a current ratio of 2.36 and a debt-to-equity ratio of 2.26. ADMA Biologics Inc has a 1 year low of $2.01 and a 1 year high of $6.47.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://www.watchlistnews.com/adam-s-grossman-buys-485000-shares-of-adma-biologics-inc-adma-stock/1703997.html.

A number of research analysts have weighed in on ADMA shares. ValuEngine cut shares of ADMA Biologics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Raymond James Financial, Inc. upgraded shares of ADMA Biologics from a “market perform” rating to an “outperform” rating and set a $5.00 price objective on the stock in a research report on Tuesday.

About ADMA Biologics

ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.

Receive News & Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.